08:00 , Feb 2, 2015 |  BioCentury  |  Politics, Policy & Law

Dr. Califf goes to Washington

FDA has had three deputy commissioners during the Obama administration ; each was expected to play a major role in shaping the agency, and none of them lived up to expectations. Last week's announcement that...
07:00 , Aug 30, 2010 |  BC Week In Review  |  Company News

Aterovax, Biomnis S.A. deal

Biomnis will market Aterovax's sPLA2 test as a service for pharmaceutical research, including clinical trials. The test for secretory phospholipase A2 ( PLA2G2A ; sPLA2) activity in plasma is in testing for diagnostic use to...
07:00 , Apr 26, 2010 |  BC Week In Review  |  Company News

Aterovax, Bertin Technologies S.A.S. sales and marketing update

Bertin's Spi-BIO subsidiary will exclusively distribute Aterovax's sPLA2 test for research use in Europe for three years. The test for secretory phospholipase A2 ( PLA2G2A ; sPLA2) activity in blood plasma is in pivotal testing...
08:00 , Jan 25, 2010 |  BC Week In Review  |  Clinical News

SPLA2 activity test: Pivotal trial data

An analysis of sPLA2 activity in serum samples from 419 patients with non-ST-segment elevation (NSTE) at baseline, but with chest pain or other clinical features indicative of ACS, showed that median sPLA2 activity as measured...
08:00 , Dec 21, 2009 |  BioCentury  |  Emerging Company Profile

Sidebar: Aterovax: Making a sPLAsh

Aterovax S.A. Paris, France Technology: Diagnostic for measuring levels of the sPLA2 biomarker Disease focus: Cardiovascular Clinical status: Clinical validation Founded: 2006 by Dominique Surun, Alain Tedgui, Ziad Mallat, Gabriel Steg, Joëlle Benessianno, Jean-Marie Freyssinet...
08:00 , Dec 21, 2009 |  BioCentury  |  Emerging Company Profile

Aterovax: Making a sPLAsh

Aterovax S.A. is developing a biomarker test for atherosclerosis to help predict the likelihood of cardiovascular events. Because measuring the sPLA2 marker provides risk information that is independent of other risk factors, the company believes...
08:00 , Nov 23, 2009 |  BC Week In Review  |  Clinical News

sPLA2 activity test: Pivotal trial data

A 5-year analysis of sPLA2 activity in 3,778 patients with stable coronary artery disease (CAD) from the placebo-controlled, postmarketing PEACE trial evaluating trandolapril to treat CAD showed that patients with the highest levels of sPLA2...